Image de couverture de livre

Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review

Fuente: arXiv

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	She, Jane, Chen, Xiaofei, Iyengar, Malini, Li, Judy
Format:	Preprint
Publié:	2026
Sujets:	Applications
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Evaluation of Individual and Trial Level Association Metrics in the Validation of a Binary Surrogate Endpoint for a True Time-to-Event Endpoint
par: Ge, Renee Y., et autres
Publié: (2026)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
par: Long, James P., et autres
Publié: (2025)

Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
par: Stijven, Florian, et autres
Publié: (2025)

Distribution-Free Selection of Low-Risk Oncology Patients for Survival Beyond a Time Horizon
par: Sesia, Matteo, et autres
Publié: (2025)

On Assessing Overall Survival (OS) in Oncology Studies
par: Hsu, Jason C.
Publié: (2025)

Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
par: Lotspeich, Sarah C., et autres
Publié: (2026)

Considerations for Single-Arm Trials to Support Accelerated Approval of Oncology Drugs
par: Lu, Feinan, et autres
Publié: (2024)

Dynamic Classification of Latent Disease Progression with Auxiliary Surrogate Labels
par: Cai, Zexi, et autres
Publié: (2024)

The Backfill i3+3 Design for Dose-Finding Trials in Oncology
par: Liu, Jiaxin, et autres
Publié: (2023)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
par: Chen, Yuxuan, et autres
Publié: (2026)

Learning from Literature: Integrating LLMs and Bayesian Hierarchical Modeling for Oncology Trial Design
par: Gong, Guannan, et autres
Publié: (2026)

Pharmacometrics-Enabled DOse OPtimization (PEDOOP) for Seamless Phase I-II Trials in Oncology
par: Yuan, Shijie, et autres
Publié: (2023)

Nonparametric Bayesian Multi-Treatment Mixture Cure Survival Model with Application in Pediatric Oncology
par: Chang, Peter, et autres
Publié: (2025)

Network Meta Analysis of Mean Survival
par: Apsemidis, Anastasios, et autres
Publié: (2025)

The Modified Combo i3+3 Design for Novel-Novel Combination Dose-Finding Trials in Oncology
par: Liu, Jiaxin, et autres
Publié: (2024)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
par: Lee, Kyong Ju, et autres
Publié: (2025)

Semiparametric Piecewise Accelerated Failure Time Model for the Analysis of Immune-Oncology Clinical Trials
par: Sunami, Hisato, et autres
Publié: (2024)

Personalized Oncology: Feasibility of Evaluating Treatment Effects for Individual Patients
par: Jang, Lydia, et autres
Publié: (2025)

Index Date Imputation For Survival Outcomes for Externally Controlled Trials
par: Coent, Q. Le, et autres
Publié: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
par: Hall, Andrew, et autres
Publié: (2025)

Statistical Inference for Heterogeneous Treatment Effect with Right-censored Data from Synthesizing Randomized Clinical Trials and Real-world Data
par: Mao, Guangcai, et autres
Publié: (2025)

A Novel Framework for Modeling Quarantinable Disease Transmission
par: Liu, Wenchen, et autres
Publié: (2025)

Analyses and Concerns in Precision Medicine: A Statistical Perspective
par: Chen, Xiaofei
Publié: (2024)

Dynamic Prediction of the Target Survival Time in Metastatic Solid Tumor Cancer Clinical Trials
par: Wang, Sidi, et autres
Publié: (2026)

Evaluating causal effects on time-to-event outcomes in an RCT in Oncology with treatment discontinuation
par: Ballerini, Veronica, et autres
Publié: (2023)

Toward Valid Generative Clinical Trial Data with Survival Endpoints
par: Chassat, Perrine, et autres
Publié: (2025)

Forecasting Medium-Horizon Alzheimer's Disease Progression: Residual Gap-Aware Transformers for 24-Month CDR-SB Change from ADNI Clinical and Biomarker Histories
par: Tong, Ran, et autres
Publié: (2026)

Bayesian Nonparametric Causal Inference for Quantile Residual Life: An Application to Alzheimer's Disease
par: Bae, Woojung, et autres
Publié: (2026)

Joint Modeling of Biomarker Cascades Along An Unobserved Disease Progression with Differentiate Covariate Effects: An Application in Alzheimer's Disease
par: Tang, Zhuojun, et autres
Publié: (2023)

Evaluating the Surrogate Index as a Decision-Making Tool Using 200 A/B Tests at Netflix
par: Zhang, Vickie, et autres
Publié: (2023)

ResSurv: Cancer Survival Analysis Prediction Model Based on Residual Networks
par: Zhai, Wankang
Publié: (2024)

Application of Markov Chains to Multiple Sclerosis Clinical Trial Data to Estimate Disease Trajectories
par: Sthanu, Uma, et autres
Publié: (2024)

Causal Judge Evaluation: Calibrated Surrogate Metrics for LLM Systems
par: Landesberg, Eddie, et autres
Publié: (2025)

Statistical Design and Rationale of the Biomarkers for Evaluating Spine Treatments (BEST) Trial
par: Sperger, John, et autres
Publié: (2025)

Surrogate Models to Predict Wave Hydrodynamics on Evolving Landscapes
par: Gharehtoragh, Mohammad Ahmadi, et autres
Publié: (2025)

A Plot is Worth a Thousand Tests: Assessing Residual Diagnostics with the Lineup Protocol
par: Li, Weihao, et autres
Publié: (2023)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
par: Li, Yuhan, et autres
Publié: (2024)

A Workflow for Evaluating Regional Treatment Effect Heterogeneity in Multi-Regional Clinical Trials
par: Zhang, Cong, et autres
Publié: (2026)

Estimation of Heterogeneous Causal Mediation Effects in a Hypertension Treatment Trial
par: Zhao, Yi, et autres
Publié: (2025)

Extending Inferences from Randomized Clinical Trials to Target Populations: A Scoping Review of Transportability Methods
par: Wang, Guanbo, et autres
Publié: (2024)